- Advertisement -
A trial of medtech Noxopharm’s (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company’s investors.
Shares in the Sydney-based company were up nearly 3 per cent this morning after Noxopharm’s independent safety committee cleared a trial of its drug Veyonda for the treatment of COVID-19 complications to move to the next stage.
As such, a final cohort of COVID-19 infected recipients in the US will receive a dosage of Veyonda, an experimental anti-cancer drug.
“The company regards this as a highly encouraging outcome given the advanced nature of COVID-19 disease in these study patients, in particular suffering serious lung dysfunction,” says…
